Partnerships and co-selling trends to watch in 2026 for healthcare and life sciences

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install partnerships and co-selling has to reflect that reality from day one.

Partnerships and co-selling in 2026 is not the same discipline it was in 2024. Seven shifts are worth naming, three of them worth acting on this quarter.

Shift one: buyers reward specificity more than ever. Generic coverage is now negative signal, not neutral. This is the single biggest lever change.

Shift two: tooling is consolidating. The horizontal all-in-one platforms are absorbing the point tools; plan for fewer vendors and more integrated data.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Partnerships and co-selling is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Shift three: AI is now assumed. The differentiator has moved from having AI to running it under a disciplined operating model.

Shift four: sourced and influenced pipeline from partners is becoming a board-level metric across categories. Instrument it whether or not your board asks yet.

Shifts five to seven affect specific segments — enterprise governance, category creation, and vertical specialisation. Read them if they touch your business; ignore them if they do not.

The trend most likely to bite: signing MOUs no one operationalises, dressed up in whatever this year's language happens to be. Watch for it.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing partnerships and co-selling properly rather than half-heartedly across three vendors.